sb 203580 has been researched along with niflumic acid in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (niflumic acid) | Trials (niflumic acid) | Recent Studies (post-2010) (niflumic acid) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 720 | 31 | 160 |
| Protein | Taxonomy | sb 203580 (IC50) | niflumic acid (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.064 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.918 | |
| Transcriptional enhancer factor TEF-3 | Homo sapiens (human) | 5.9 | |
| G-protein coupled receptor 35 | Homo sapiens (human) | 1.28 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belsey, MJ; Davies, AR; Kozlowski, RZ; Witchel, HJ | 1 |
1 other study(ies) available for sb 203580 and niflumic acid
| Article | Year |
|---|---|
Inhibition of ERK and JNK decreases both osmosensitive taurine release and cell proliferation in glioma cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Anthracenes; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dicumarol; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imidazoles; Ion Channels; JNK Mitogen-Activated Protein Kinases; Necrosis; Niflumic Acid; Nitrobenzoates; Osmolar Concentration; Pyridines; Rats; Taurine | 2007 |